Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023
SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023. Pavel Printsev, Director of Business Development of Bridge Biotherapeutics, will provide an overview of the company as well as an...
Exclusive Pepaminto topper wins CES® 2023 Innovation Award
Mattress Topper developed exclusively for the Apple Watch®. MÜNSTER, Germany, Jan. 3, 2023 /PRNewswire/ -- Freezing, shivering, sweating - everyone's nighttime perception of warmth is different. The German Start-up Variowell Development asked 3.300 consumers in 5 countries globally. Over 50% answered that they or their partner often feel too hot often at...
Sisram Medical to Present Virtually at the 25th Annual Needham Growth Conference
CAESAREA, Israel, Jan. 3, 2023 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused brands, including Energy Based Devices, Injectables, Aesthetic and Digital Dentistry, Personal Care and more, today announced...
Call for Application for 2023 Tsinghua Amgen Scholars Program
BEIJING, Jan. 3, 2023 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Through the 8- or 10-weeks summer program, outstanding undergraduates from across the globe can undertake research projects under...
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA “Study May Proceed” Letter for PRO1160, a...
PRO1184 first-in human study initiated and first patients dosed PRO1160 first-in-human study cleared for initiation in the US Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform SUZHOU, China and WOODINVILLE, Wash., Jan. 3, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics,...
Steakholder Foods® Receives Grant of up to $1M for Collaboration with Umami Meats to 3D Bio-Print Structured Cultivated Fish Products
The company's collaborative initiative with its 3D bio-printer is a significant step forward in the company's commercialization strategy for 2023 REHOVOT, Israel, Jan. 3, 2023 /PRNewswire/ -- Steakholder Foods (Nasdaq: STKH), an international deep-tech food company at the forefront of the cultivated meat industry, has received its first grant to develop 3D-printed...
Clarivate and the Chinese Academy of Sciences Release Annual Joint Report to Identify 165 Research Fronts
Selecting significant research specialties in sciences and social sciences LONDON, Jan. 3, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, and the Chinese Academy of Sciences (CAS) today released Research Fronts 2022, their ninth annual collaborative report. The report identifies...
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava in China in 2023-- --Leverage both in-house discovery and strategic business development to establish industry leadership and global footprint-- SHANGHAI, Jan. 3, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused...
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday,...
CGTN: China monitors coronavirus mutations to adjust COVID-19 response
BEIJING, Jan. 3, 2023 /PRNewswire/ -- With China loosening its COVID-19 restrictions, some experts have expressed concern that China's relaxation of COVID-19 limitations will enhance the likelihood of the virus mutating. "It is a worry," said CNN, citing William Schaffner, professor at the Division of Infectious Diseases of Vanderbilt University Medical Center in Nashville City, Tennessee State, and medical...
